The Role of ddPCR in CML
By Kerri Fitzgerald - Last Updated: September 29, 2022Blood Cancers Today Associate Editor Jerald Radich, MD, discusses the role of ddPCR for CML in the age of targeted therapies. He spoke with Blood Cancers Today about the topic ahead of the presentation at the SOHO Annual Meeting.
Post Tags:SOHO 2022
Advertisement
Related Posts
Mice with CML who were given a synthetic version of miR-142 lived much longer and were even cured.
Dr. Radich reflects on lessons in cowboy medicine, the genetics of luck, and a serendipitous meeting.
The FDA also announced it approved a new capsule dosage form of bosutinib.
Dr. Cortes speaks about the plenary session he delivered during the Eleventh Annual Meeting of SOHO.
Researchers reviewed data from 107 patients with CML who developed a T315I mutation in BCR-ABL1.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.